CD8A and cancer: Therefore, we attempted to validate the value of the CD3+ and CD8+ T cell-imputed immunoscore as a prognostic biomarker in cancer patients treated with ICIs and to support its utility as a “reference” or “control” in machine learning (ML)/artificial intelligence-based studies for biomarker development in the context of ICI and other immunotherapies when using transcriptomic data.